Clinical Trial Update: Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating a combination of interleukin-2, interferon-alpha and bevacizumab in metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Interferon-alpha (interferon alpha)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: University of Aarhus | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: UNKNOWN